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We read with interest the paper of Bournia and colleagues 
that anticentromere antibody (ACA)-positive primary 
Sjögren’s syndrome (SS) shows a clinical phenotype 
intermediate between ACA-negative SS and systemic 
sclerosis (SSc) [1]. In our past study investigating the 
clinical features of 62 patients with positive ACA, only 
one patient had typical CREST syndrome, 9 patients had 
Raynaud’s phenomenon (8 with sclerodactyly, telangiec-
tasia or calcinosis), while rheumatoid arthritis (RA) was 
the most common diagnosis (21 patients) [2]. Th  ereafter, 
we investigated whether ACA-positive RA patients have 
distinctive clinical features compared to general RA 
patients [3] and found that the high titer group (over 
1:320) was associated with Raynaud’s phenomenon more 
often. Th  is result suggests that RA patients are also 
aﬀ  ected by high titer ACA, similar to SS patients.
Recently, anti-cyclic citrullinated peptide (anti-CCP) 
has emerged as a useful diagnostic tool in RA. In order to 
examine any association between anti-CCP and ACA 
positivity in RA patients, we investigated 81 ACA-
positive patients using an anti-CCP test from 2007 until 
May 2010 (Table 1). Interestingly, out of 34 RA patients, 
70.6% (24) were positive for anti-CCP, and there was no 
case of accompanying Raynaud’s phenomenon among 
them. For ACA-positive RA with negative anti-CCP, only 
one patient (10%) had Raynaud’s phenomenon, similar to 
our past result (15.7%) [3]. In contrast, the incidence of 
interstitial pulmonary disease was 11.8% (4 out of 34), 
higher than in our past report (4.2%) [3], and this was 
unrelated to anti-CCP positivity. Th  ese results suggest 
that the inﬂ  uence of anti-CCP is greater than ACA in 
determining the disease entity and masks even the inﬂ  u-
ence of ACA on the clinical phenotype inter  mediate with 
SSc. Th   is is supported by a report that anti-CCP is useful 
for discriminating between SSc-RA and SSc alone [4].
We think that the inﬂ  uence of anti-CCP on the disease 
entity is greater than that of ACA. Th   is would mean that 
the diagnostic impact of disease-associated auto  anti-
bodies is diﬀ  erent depending on their natures, although 
they can exert some inﬂ   uence on the expression of 
speciﬁ  c clinical features. Th   erefore, although a patient is 
positive for ACA, we suppose that clinical symptoms 
may be diﬀ  erent depending on the kind of coexisting 
auto antibody.
(Th  e information in our study was recorded in a 
manner that subjects cannot be identiﬁ  ed directly, so this 
study was not reviewed by our internal review board 
under the US Department of Health and Human Services 
regulations at 45 CFR 46.101(b)(4). Under the same 
regulations, informed consent was also not required.) © 2010 BioMed Central Ltd
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Table 1. The distribution of anticentromere antibody-
positive patients according to anti-cyclic citrullinated 
peptide results
 Anticentromere antibody-positive (n = 81)a
    Anti-CCP positive  Anti-CCP negative 
    (n = 29)b  (n = 52)  P-valuec
RA   24  10  <0.05
 with  Raynaud  0/24  1/10  0.116
 with  sicca  2/24  0/10  0.347
 with  IPD  3/24  1/10  0.837
Other diseasesd 5  42 
aAnticentromere detected by autoimmune target (AIT) test (ImmunoThink 
Co., Seoul, Republic of Korea). bAnti-CCP detected by second generation ELISA 
(Axis-Shield, Dundee Scotland/Immco Diagnostics, Buff  alo, USA). cChi-square 
test (P < 0.05). dOther diseases include systemic sclerosis, systemic lupus 
erythematosus, Raynaud’s phenomenon, Sjögren’s syndrome, unspecifi  ed 
rheumatism and osteoarthritis. CCP, cyclic citrullinated peptide; IPD, interstitial 
pulmonary disease; RA, rheumatoid arthritis.
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ACA, anticentromere antibody; CCP, cyclic citrullinated peptide; ELISA, 
enzyme-linked immunosorbent assay; RA, rheumatoid arthritis; SS, Sjögren’s 
syndrome; SSc, systemic sclerosis.
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